Health Economic Studies of Surfactant Replacement Therapy in Neonates with Respiratory Distress Syndrome: A Systematic Literature Review

[1]  L. Citrome,et al.  Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update , 2022, Annals of Internal Medicine.

[2]  A. Greenough,et al.  Outcomes following less-invasive-surfactant-administration in the delivery-room. , 2022, Early human development.

[3]  C. Federici,et al.  Cost-saving effect of early less invasive surfactant administration versus continuous positive airway pressure therapy alone for preterm infants with respiratory distress syndrome , 2021, European journal of hospital pharmacy : science and practice.

[4]  Heather B. Blunt,et al.  PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews , 2021, Systematic Reviews.

[5]  J. V. Galindo,et al.  PRS8 Budget IMPACT Analysis of LESS Invasive Surfactant Administration (LISA) Technique As EARLY Rescue Strategy for Preterm Infants with Respiratory Distress Syndrome in Spain , 2020 .

[6]  C. Rivetti,et al.  In vitro characterization and in vivo comparison of the pulmonary outcomes of Poractant alfa and Calsurf in ventilated preterm rabbits , 2020, PloS one.

[7]  M. Chakraborty,et al.  Management of Respiratory Distress Syndrome in Preterm Infants In Wales: A Full Audit Cycle of a Quality Improvement Project , 2020, Scientific Reports.

[8]  G. Greisen,et al.  European Consensus Guidelines on the Management of Respiratory Distress Syndrome – 2019 Update , 2019, Neonatology.

[9]  K. Sekar,et al.  Health Economics and Outcomes of Surfactant Treatments for Respiratory Distress Syndrome Among Preterm Infants in US Level III/IV Neonatal Intensive Care Units. , 2019, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[10]  Xiaohua Yan,et al.  Comparison of the efficacy and safety of bovine lung phospholipid and poractant alfa injections in the treatment of neonatal hyaline membrane disease with continuous positive airway pressure , 2019 .

[11]  R. Yagudina,et al.  PRS50 - COST-EFFECTIVENESS ANALYSIS OF SURFACTANT THERAPY FOR THE TREATMENT OF RESPIRATORY DISTRESS SYNDROME NEWBORN IN THE RUSSIAN FEDERATION , 2018, Value in Health.

[12]  Sara Brown,et al.  Poractant Alfa Versus Beractant for Neonatal Respiratory Distress Syndrome: A Retrospective Cost Analysis. , 2018, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[13]  F. Parazzini,et al.  Neonatal respiratory distress syndrome: are risk factors the same in preterm and term infants? , 2017, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[14]  Fiona B Wertheimer,et al.  Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future , 2017, Pediatric Research.

[15]  L. Krasnova,et al.  Clinical And Economic Analysis Of Two Surfactants For The Prevention And Treatment Of Respiratory Distress Syndrome , 2016 .

[16]  J. Beyene,et al.  Association of Noninvasive Ventilation Strategies With Mortality and Bronchopulmonary Dysplasia Among Preterm Infants: A Systematic Review and Meta-analysis. , 2016, JAMA.

[17]  D. Jayne,et al.  SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[18]  P. Davis,et al.  Prophylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants. , 2016, The Cochrane database of systematic reviews.

[19]  T. Stevens,et al.  Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants. , 2015, The Cochrane database of systematic reviews.

[20]  C. L. Hermansen,et al.  Newborn Respiratory Distress. , 2015, American family physician.

[21]  A. Riskin,et al.  A randomized pilot study comparing heated humidified high‐flow nasal cannulae with NIPPV for RDS , 2015, Pediatric pulmonology.

[22]  R. Ravasio,et al.  Analysis of the cost-effectiveness of surfactant treatment (Curosurf®) in respiratory distress syndrome therapy in preterm infants: early treatment compared to late treatment , 2014, Italian Journal of Pediatrics.

[23]  W. Carlo,et al.  Surfactant Replacement Therapy for Preterm and Term Neonates With Respiratory Distress , 2014, Pediatrics.

[24]  K. Sekar,et al.  Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study , 2011, Journal of Perinatology.

[25]  J. Carlin,et al.  Minimally-invasive surfactant therapy in preterm infants on continuous positive airway pressure , 2012, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[26]  W. Göpel,et al.  Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial , 2011, The Lancet.

[27]  H. Halliday,et al.  Surfactants: past, present and future , 2008, Journal of Perinatology.

[28]  W. Engle.  Surfactant-Replacement Therapy for Respiratory Distress in the Preterm and Term Neonate , 2008, Pediatrics.

[29]  G. Greisen,et al.  Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation. , 1999, Pediatrics.

[30]  T O Jefferson,et al.  Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.

[31]  W. Richardson,et al.  The well-built clinical question: a key to evidence-based decisions. , 1995, ACP journal club.